The Type A meeting provides a clearer path to resubmission, but the timeline and success remain uncertain. Monitor for progress on the dual-source manufacturing strategy and any FDA reinspection of the current contract manufacturer. The stock is likely to trade on binary resubmission and approval news, not this procedural update.
Price Chart
Executive Summary
Grace Therapeutics announced receipt of FDA Type A meeting minutes regarding the Complete Response Letter (CRL) for its GTx-104 NDA. The CRL did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The company is advancing a dual-source manufacturing strategy, including a U.S.-based contract manufacturer, toward NDA resubmission. This is a procedural update that removes some regulatory uncertainty but does not change the fundamental binary risk of the resubmission outcome.
Key Facts
- Received FDA Type A meeting minutes for GTx-104 NDA resubmission path.
- CRL did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data.
- Pursuing a dual-source manufacturing strategy, adding a U.S.-based contract manufacturer.
- Cash and cash equivalents of $17.0 million as of March 31, 2026.
- Outstanding warrants could provide up to $15.0 million in gross proceeds if exercised.
- Company has no debt.
Financial Impact
No financial figures reported in this filing. The company reported $17.0M in cash and $15.0M potential warrant proceeds.
Risk Factors
- FDA reinspection of current contract manufacturer may not result in a compliant status.
- Technology transfer to second-source CDMO may face delays or fail to generate required data.
- Company may need additional capital before NDA resubmission or approval.
- Resubmission may not comprehensively address all CRL items, leading to further review delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-029837 |
| Document: ef20078866_8k.htm | 0001140361-26-029837 |
| Document: ef20078866_ex99-1.htm | 0001140361-26-029837 |
| Document: 0001140361-26-029837-index-headers.html | 0001140361-26-029837 |
| Document: 0001140361-26-029837-index.html | 0001140361-26-029837 |
| Document: 0001140361-26-029837.txt | 0001140361-26-029837 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers